# Adaptive Proteomic Changes in Protein Metabolism and Mitochondrial Alterations Associated with Resistance to Trastuzumab and Pertuzumab Therapy in HER2-Positive Breast Cancer

## TL;DR

This study identifies proteomic changes and mitochondrial alterations linked to resistance in HER2-positive breast cancer, offering new targets for treatment.

## Contribution

The study reveals novel proteomic and mitochondrial mechanisms underlying resistance to anti-HER2 therapies in breast cancer.

## Key findings

- 618 differentially expressed proteins were identified, including 83 overexpressed and 118 downregulated proteins.
- Key alterations in protein metabolism, mitochondrial function, and signaling pathways like MAPK, TNF, and TGFβ were found.
- Proteins ANXA1, SLC2A1, and PPIG were identified as contributors to tumor progression and resistance.

## Abstract

HER2 (human epidermal growth factor receptor 2) is overexpressed in approximately 15–20% of breast cancers, leading to aggressive tumour growth and poor prognosis. Anti-HER2 therapies, such as trastuzumab and pertuzumab, have significantly improved the outcomes for patients with HER2-positive breast cancer by blocking HER2 signalling. However, intrinsic and acquired resistance remains a major clinical challenge, limiting the long-term effectiveness of these therapies. Understanding the mechanisms of resistance is essential for developing strategies to overcome it and improve the therapeutic outcomes. We generated multiple HER2-positive breast cancer cell line models resistant to trastuzumab and pertuzumab combination therapy. Using mass spectrometry-based proteomics, we conducted a comprehensive analysis to identify the mechanisms underlying resistance. Proteomic analysis identified 618 differentially expressed proteins, with a core of 83 overexpressed and 118 downregulated proteins. Through a series of advanced bioinformatics analyses, we identified significant protein alterations and signalling pathways potentially responsible for the development of resistance, revealing key alterations in the protein metabolism, mitochondrial function, and signalling pathways, such as MAPK, TNF, and TGFβ. These findings identify mitochondrial activity and detoxification processes as pivotal mechanisms underlying the resistance to anti-HER2 therapy. Additionally, we identified key proteins, including ANXA1, SLC2A1, and PPIG, which contribute to the tumour progression and resistance phenotype. Our study suggests that targeting these pathways and proteins could form the basis of novel therapeutic strategies to overcome resistance in HER2-positive breast cancer.